ApoE-Targeting Increases the Transfer of Solid Lipid Nanoparticles with Donepezil Cargo across a Culture Model of the Blood–Brain Barrier
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Pharmacological treatment of central nervous system (CNS) disorders is difficult, because the blood–brain barrier (BBB) restricts the penetration of many drugs into the brain. To solve this unmet therapeutic need, nanosized drug carriers are the focus of research efforts to develop drug delivery systems for the CNS. For the successful delivery of nanoparticles (NPs) to the brain, targeting ligands on their surface is necessary. Our research aim was to design a nanoscale drug delivery system for a more efficient transfer of donepezil, an anticholinergic drug in the therapy of Alzheimer’s disease across the BBB. Rhodamine B-labeled solid lipid nanoparticles with donepezil cargo were prepared and targeted with apolipoprotein E (ApoE), a ligand of BBB receptors. Nanoparticles were characterized by measurement of size, polydispersity index, zeta potential, thermal analysis, Fourier-transform infrared spectroscopy, in vitro release, and stability. Cytotoxicity of nanoparticles were investigated by metabolic assay and impedance-based cell analysis. ApoE-targeting increased the uptake of lipid nanoparticles in cultured brain endothelial cells and neurons. Furthermore, the permeability of ApoE-targeted nanoparticles across a co-culture model of the BBB was also elevated. Our data indicate that ApoE, which binds BBB receptors, can potentially be exploited for successful CNS targeting of solid lipid nanoparticles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology
Kovalevich, J., & Langford, D. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-640-5_2 · Cited by 1,005
Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.
Kreuter, J., Shamenkov, D., Petrov, V., Ramge, P., Cychutek, K., Koch-Brandt, C., & Alyautdin, R. (2002) · Journal of drug targeting · doi:10.1080/10611860290031877 · Cited by 801
The hCMEC/D3 cell line as a model of the human blood brain barrier
Weksler, B., Romero, I. A., & Couraud, P.-O. (2013) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-10-16 · Cited by 753 · cited 1×
“4 μM hydrocortisone, 100 μg/mL heparin, 1 ng/mL basic fibroblast growth factor, ITS, and 50 μg/mL gentamicin [27].”
A new blood–brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes
Nakagawa, S., Deli, M. A., Kawaguchi, H., Shimizudani, T., Shimono, T., Kittel, Á., Tanaka, K., & Niwa, M. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2008.12.002 · Cited by 728 · cited 2×
“Isolation of primary rat brain endothelial cells (RBECs), pericytes, and astrocytes were performed according to the method described in our previous studies [7,24,25].”
MethodSelf-citationDrug delivery to the central nervous system by polymeric nanoparticles: What do we know?
Kreuter, J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.008 · Cited by 554
Kedmi, R., Ben-Arie, N., & Peer, D. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.05.027 · Cited by 546 · cited 1×
“Negatively charged lipid NPs are generally less toxic and have higher stability compared to positively charged NPs [48].”
BackgroundApolipoprotein E in lipoprotein metabolism, health and cardiovascular disease
Marais, A. D. (2019) · Pathology · doi:10.1016/j.pathol.2018.11.002 · Cited by 382 · cited 4×
“The expression of LDLR and LRP family members is high at the BBB, and these receptors are also present on neurons [15,16,44].”
BackgroundMethodInfluentialAcetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection
Singh, M., Kaur, M., Kukreja, H., Chugh, R., Silakari, O., & Singh, D. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.09.050 · Cited by 364
Misra, S., Chopra, K., Sinha, V. R., & Medhi, B. (2016) · Drug Delivery · doi:10.3109/10717544.2015.1089956 · Cited by 136 · cited 1×
“Classical AD drug galantamine was also formulated in lipid NPs [40], but we found no studies focusing on donepezil.”
BackgroundNeurotheranostics as Personalized Medicines
Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124
Cited by
Lipid Nanoparticles for Drug Delivery
Xu, L., Wang, X., Liu, Y., Yang, G., Falconer, R. J., & Zhao, C.-X. (2022) · Advanced NanoBiomed Research · doi:10.1002/anbr.202100109 · Cited by 545
Functionalized Nanomaterials Capable of Crossing the Blood–Brain Barrier
Zha, S., Liu, H., Li, H., Li, H., Wong, K.-L., & All, A. H. (2024) · ACS Nano · doi:10.1021/acsnano.3c10674 · Cited by 378
Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB
Satapathy, M. K., Yen, T.-L., Jan, J.-S., Tang, R.-D., Wang, J.-Y., Taliyan, R., & Yang, C.-H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081183 · Cited by 318
“Donepezil (an anti-Alzheimer’s drug), when tailored to ApoE-targeted and SLN-based formulations, the in vitro study findings showed that it has enhanced drug delivery with a favorable release profile in CMEC/D3 brain endothelial cells and human SH-SY5Y neuronal cells [223].”
Lipid nanoparticle-mediated drug delivery to the brain
Khare, P., Edgecomb, S. X., Hamadani, C. M., Tanner, E. E. L., & S Manickam, D. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114861 · Cited by 187
Teixeira, M. I., Lopes, C. M., Amaral, M. H., & Costa, P. C. (2023) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2022.112999 · Cited by 154
Metadata
- Authors
- Topal, G. R., Mészáros, M., Porkoláb, G., Szecskó, A., Polgár, T. F., Siklós, L., Deli, M. A., Veszelka, S., & Bozkir, A.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2020-12-29
- Volume
- 13
- Issue
- 1
- Pages
- 38
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W3115389925
- Cited by
- 132
- References
- 11
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.